Welcome to our dedicated page for Stevanato Group S.p.A. SEC filings (Ticker: STVN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Stevanato Group S.p.A. filings document the company’s reporting as a foreign private issuer and its business in drug containment, drug delivery and diagnostic solutions. Form 6-K reports furnish interim financial statements, results press releases, investor presentations and conference call materials covering revenue trends, segment performance, high-value solutions, margins, guidance, capacity expansion and risk disclosures.
Governance filings also include shareholder meeting notices, explanatory reports, sustainability reporting, committee reports, remuneration policy materials, dividend allocation matters and director slate information. These documents describe the company’s financial reporting framework, board and committee processes, shareholder voting matters and public-company disclosures for STVN.
Stevanato Group S.p.A. reported unaudited Q3 and nine‑month 2025 results showing higher sales and profitability. Q3 revenue was €303.2 million (up from €277.9 million), with operating profit of €52.7 million and net profit of €36.1 million; basic EPS was €0.13 (vs €0.11). Nine‑month revenue reached €839.8 million (vs €773.4 million), operating profit €128.7 million, and net profit €92.3 million.
Growth was led by the Biopharmaceutical and Diagnostic Solutions segment (Q3 €266.7 million), including a step‑up in high‑value solutions (€147.9 million vs €100.4 million). The Engineering segment posted €36.4 million. Cash from operations strengthened to €192.0 million year‑to‑date, while capex of €187.7 million supported the ramp‑up of the Fishers (U.S.) and Latina (Italy) sites. The company entered a rent‑to‑buy agreement for its Zhangjiagang, China facility and reported cash of €113.3 million at period end.
The effective tax rate improved to 25.2% for the nine months, reflecting Italy’s one‑year “IRES premiale” benefit. Net foreign exchange effects were a loss of €14.0 million year‑to‑date. One customer represented 12.6% of nine‑month revenue.
Artisan Partners reported beneficial ownership of 2,733,782 ordinary shares of Stevanato Group S.p.A., representing 5.5% of the class based on 49,604,649 shares outstanding as of 06/12/2025. The filing shows shared voting power of 2,316,046 and shared dispositive power over 2,733,782 shares, with no sole voting or dispositive power reported. The shares were acquired for discretionary clients of Artisan Partners Limited Partnership and the filers certify the holdings were acquired in the ordinary course of business and not for the purpose of changing or influencing control.